Limited evidence suggests that GLP-I may also preserve ventricular function and improve outcomes in human subjects with heart failure or myocardial infarction (11,12). [...] both exenatide and liraglutide reduce blood pressure, body weight, and plasma lipid profiles in subjects with type 2 diabetes (13), raising the hope that longterm treatment with these agents may reduce the incidence of cardiovascular events. However, two safety issues have been raised - pancreatitis and medullary carcinoma of the thyroid.
No takes yet. Share an insight, caveat, or question.
Sherman et al. (2020) studied this question.